Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GDC-0927 in ER+ Breast Cancer
NCT02316509Phase 1Completed
- Sponsor
- Genentech
- Start
- Mar 2015
- Primary completion
- Jan 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of GDC-0927 in breast cancer (2 arms), sponsored by Genentech. Primary endpoints: Maximum Tolerated Dose / Recommended Phase II Dose and Adverse Events up to 3 years. Started Mar 2015; status: completed.
02
Drugs
GDC-0927
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02316509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316509.